These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 8840986)
1. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Lübbe AS; Bergemann C; Huhnt W; Fricke T; Riess H; Brock JW; Huhn D Cancer Res; 1996 Oct; 56(20):4694-701. PubMed ID: 8840986 [TBL] [Abstract][Full Text] [Related]
2. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Lübbe AS; Bergemann C; Riess H; Schriever F; Reichardt P; Possinger K; Matthias M; Dörken B; Herrmann F; Gürtler R; Hohenberger P; Haas N; Sohr R; Sander B; Lemke AJ; Ohlendorf D; Huhnt W; Huhn D Cancer Res; 1996 Oct; 56(20):4686-93. PubMed ID: 8840985 [TBL] [Abstract][Full Text] [Related]
3. A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996. Gallo JM; Hafeli U Cancer Res; 1997 Jul; 57(14):3063-5. PubMed ID: 9230223 [No Abstract] [Full Text] [Related]
4. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer]. Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420 [TBL] [Abstract][Full Text] [Related]
5. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245 [TBL] [Abstract][Full Text] [Related]
6. Clinical applications of magnetic drug targeting. Lübbe AS; Alexiou C; Bergemann C J Surg Res; 2001 Feb; 95(2):200-6. PubMed ID: 11162046 [TBL] [Abstract][Full Text] [Related]
7. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824 [TBL] [Abstract][Full Text] [Related]
8. Antitumor, hematostimulative and radioprotective action of water-soluble derivative of propolis (WSDP). Orsolić N; Basić I Biomed Pharmacother; 2005 Dec; 59(10):561-70. PubMed ID: 16202559 [TBL] [Abstract][Full Text] [Related]
9. [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma]. Qu QL; Zhang YG; Yang LZ; Sun L Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):257-60. PubMed ID: 16875622 [TBL] [Abstract][Full Text] [Related]
10. Drug eruption due to intravesical instillations of both epirubicin and mitomycin C. Okumura A; Oishi N; Kaji K; Imamura T; Fuse H J Dermatol; 2009 Jul; 36(7):419-22. PubMed ID: 19583691 [TBL] [Abstract][Full Text] [Related]
11. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325 [TBL] [Abstract][Full Text] [Related]
12. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
13. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137 [TBL] [Abstract][Full Text] [Related]
14. NTP Studies of Magnetic Field Promotion (DMBA Initiation) in Female Sprague-Dawley Rats (Whole-body Exposure/Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Aug; 489():1-148. PubMed ID: 12563342 [TBL] [Abstract][Full Text] [Related]
15. Localization and distribution of magnetic chemotherapeutic drugs with magnetic targeting in rat brain. Li AM; Zhang CX; Fu XP; Zhang ZW; Xue QH; Yan RM; Yi LH Chin Med J (Engl); 2005 May; 118(10):824-7. PubMed ID: 15989762 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence]. Wu ZB; Lin GB; Chen BJ; Wu ZM; Rong RM Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):507-9. PubMed ID: 16188156 [TBL] [Abstract][Full Text] [Related]
17. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859 [TBL] [Abstract][Full Text] [Related]
18. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Tang T; Zheng JW; Chen B; Li H; Li X; Xue KY; Ai X; Zou SQ Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):303-7. PubMed ID: 17548256 [TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
20. [Experiment and clinical application of targeting treatment with adriamycin magnetic albumin microspheres in human gastric carcinoma]. Tao K; Chen D; Wang G; Bai Z; Lu X; Tian Y; Wu Z; Hu F; Nie X Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):205-7. PubMed ID: 11829819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]